Drug Patent Watch

DECEMBER 10, 2024

The pharmaceutical industry has undergone significant changes over the past decade, with a growing trend towards outsourcing key aspects of research, development, and manufacturing to third-party vendors. The Rise of Integrated CDMOs The global biotechnology and pharmaceutical services outsourcing market size was valued at $70.48

Drug Development

Drug Patent Watch

DECEMBER 30, 2024

This article aims to provide a comprehensive overview of the key aspects of the regulatory framework, highlighting the requirements and challenges faced by pharmaceutical companies seeking to introduce generic drugs into the Japanese market. Retrieved from [link] Japan Pharmaceutical Manufacturers Association. Freyr Solutions.

Drug Development

Chemical Biology and Drug Design

JULY 25, 2025

Comprehensive ADMET analysis indicated favorable pharmaceutical properties, including oral absorption via the BBB and GI tract. For cholinesterase inhibition, compounds 8 and 13 outperformed Galantamine against AChE, and compound 9 showed the strongest BuChE inhibition.

Pharmaceuticals

Chemical Biology and Drug Design

JANUARY 5, 2025

5(4-Hydroxyphenyl)-2-(N-Phenyl amino)-1,3,4-Oxadiazole (Hppo) can considered as a versatile agent in designing novel pharmaceuticals. Thus, our findings can provide novel and versatile compounds for the development of multidirectional drugs in the pharmaceutical industry.

Bioinformatics

Drug Patent Watch

JULY 24, 2025

Why Your Law Firm's Playbook May Be Holding You Back As the pharmaceutical industry continues to evolve at breakneck speed, one thing remains constant: the importance of a robust patent strategy. Read on to discover the Patent Playbook your law firm may not be sharing with you: [link] #patentstrategy #pharmaceuticals #innovation"

Pharmaceutical Companies

Drug Target Review

JULY 1, 2025

Regulatory backing The pharmaceutical industry is often open to innovation in principle, but the demands of regulatory compliance can slow the adoption of emerging technologies – particularly those that challenge conventional trial design.

Clinical Trials

Drug Patent Watch

JANUARY 15, 2025

The pharmaceutical industry is highly dynamic, with frequent filings and updates that require timely access to information[2]. Limited Search Filters While Google Patents offers basic search functionalities, it lacks advanced filters specific to pharmaceuticals. Implications for Pharmaceutical Stakeholders 1.

Drugs

Drug Patent Watch

MAY 19, 2025

"Revolutionizing the Pharmaceutical Industry: How AI-Powered Portfolio Management is Changing the Game As the pharmaceutical landscape continues to evolve, companies are under increasing pressure to optimize their portfolios and stay ahead of the competition. link] #pharmaceuticals #portfoliooptimization #AIinpharma"

Pharmaceuticals

Drug Patent Watch

DECEMBER 12, 2024

This approach not only helps maintain market exclusivity but also ensures a steady revenue stream for pharmaceutical companies. Understanding the Pharmaceutical Market Dynamics The pharmaceutical industry is a complex ecosystem where branded drugs and generics coexist, each playing a vital role in patient care and market dynamics.

Licensing

Drug Patent Watch

DECEMBER 10, 2024

India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. The country’s pharmaceutical sector has experienced substantial growth over the years, driven by both domestic and international demand for affordable and high-quality medicines.

Government

Chemical Biology and Drug Design

JUNE 19, 2025

ABSTRACT Fused pyrimidine scaffolds serve as a flexible and versatile foundational heterocycle in the field of pharmaceutical development. Thienopyrimidines exhibit multifarious features, mainly, this is due to their structural resemblance with purine bases, such as guanine and adenine.

FDA Approval

Drug Target Review

JUNE 11, 2025

Multimodal language models Generative AI models (GenAI) in the pharmaceutical field have reached the highest level of attention with the Nobel Prizes to Demis Hassabis and John Jumper for AlphaFold, which can predict protein structures. This approach limits the transformative potential of the technology.

Drugs

Drug Patent Watch

DECEMBER 9, 2024

In the vast realm of pharmaceutical research and development, there’s a fascinating intersection between ancient wisdom and modern science. “Pharmacognosy is the bridge between traditional medicine and modern pharmaceutical science, offering a treasure trove of potential new drugs waiting to be discovered.”

Drugs

DrugBank

OCTOBER 30, 2024

At DrugBank, we’re dedicated to empowering pharmaceutical researchers with data that drives impactful results. Your Need for Accessible, High-Quality Data—Solved Pharmaceutical research and healthcare innovation demand timely access to comprehensive, up-to-date data. In fact, poor data quality is estimated to cost U.S.

Production

Drug Patent Watch

OCTOBER 30, 2024

The pharmaceutical industry is known for its complex regulatory environment and lengthy product development processes. One often overlooked aspect of this industry is the potential benefits of abandoned and expired patents.

Pharmaceuticals

BioPharma Drive: Drug Pricing

JULY 8, 2025

Multiple deals have been struck by large companies such as Roche and Novartis, suggesting pharmaceutical firms believe degraders have only begun to show their promise.

Targeted Protein Degradation

The Pharma Data

JUNE 16, 2025

Teva and Fosun Pharma Forge Strategic Partnership to Develop and Commercialize Innovative Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology Teva Pharmaceutical Industries Ltd. and Shanghai Fosun Pharmaceutical (Group) Co., About Fosun Pharma (Shanghai Fosun Pharmaceutical (Group) Co.,

Therapies

Drug Patent Watch

JUNE 23, 2025

Patent filings represent one of the most valuable yet underutilized sources of competitive intelligence in the pharmaceutical industry. By systematically monitoring and analyzing these documents…

Pharmaceuticals

Drug Target Review

JULY 3, 2025

It is becoming increasingly evident that generative artificial intelligence (GenAI) is a resourceful tool for helping pharmaceutical companies reduce manual tasks required by clinical trials.

Drug Development

LifeSciVC

MAY 14, 2025

1,2,3 Among a long list of innovations, the lowest hanging fruit for commercialization is the use of microgravity-based crystallization to enhance high-value pharmaceuticals. Pharmaceuticals are among the worlds most valuable materials by weight leading branded drugs, particularly biologics, carry list prices that often exceed $1M per kg.

Science

PPD

OCTOBER 31, 2024

As the pharmaceutical industry continues to evolve, drug developers encounter new challenges and opportunities in their pursuit of innovation. From adapting to complex new trial designs to embracing cutting-edge technologies, staying ahead requires a deep understanding of the current landscape.

Drug Development

Drug Target Review

JUNE 9, 2025

A personal journey to Alltrna Michelle Werner’s career has spanned over 20 years in the pharmaceutical industry, where she developed her expertise in oncology drug development at leading companies such as Bristol Myers Squibb, AstraZeneca, and Novartis.

Disease

Drug Target Review

DECEMBER 11, 2024

For small- and medium-sized pharmaceutical companies, outsourcing represents a strategic leap forward, offering a gateway to unparalleled expertise and cutting-edge analytical technologies. Such an approach ensures reliable preclinical toxicology data and supports the transition of innovative therapies from the lab to clinical trials.

International

The Pharma Data

JUNE 9, 2025

This new chapter in the strategic partnership between WuXi Biologics and VISEN Pharmaceuticals underscores a shared commitment to innovation, localization, and improved patient care. VISEN Pharmaceuticals expects to obtain regulatory approval for lonapegsomatropin in China by 2025. Chen said. “By

Therapies

Drug Target Review

JUNE 16, 2025

Mass spectrometry imaging (MSI) enables the direct detection and quantitation of active pharmaceutical ingredients (APIs) and metabolites within tissue sections, making it widely regarded as a promising technique in the field of pharmacology and toxicology.

Drugs

The Pharma Data

JULY 2, 2025

Based on those findings, and in consultation with Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), Asahi Kasei Pharma is moving forward with a focused effort to evaluate the drug’s clinical utility in a broader patient population. Source link

Trials

Broad Institute

JUNE 11, 2025

Global Head of Research and Early Development for Cardiovascular, Renal, and Immunology at Bayer’s Pharmaceuticals Division. Our shared commitment is to explore novel technologies and therapeutic targets in various cardiovascular and renal diseases to help deliver new treatment options to patients in need,” said Andrea Haegebarth, Ph.D.,

Disease

The Pharma Data

JUNE 25, 2025

Novartis Finalizes Acquisition of Regulus Therapeutics, Strengthening Its Renal Disease Portfolio with Promising ADPKD Therapy Novartis AG, a leading global pharmaceutical company, has officially completed its acquisition of Regulus Therapeutics Inc. , a biotechnology firm known for its expertise in microRNA-targeting therapies.

RNA

Drug Target Review

OCTOBER 30, 2024

He has over 20 years’ experience in biomedical research and pharmaceutical drug discovery. About the author Anirban Datta, Head of Discovery Biology at Verseon International Corporation Anirban Datta PhD is the head of discovery biology at Verseon International Corporation.

Treatment

The Pharma Data

JUNE 25, 2025

Strategic Collaboration with Ionis Pharmaceuticals Salanersen originated from Biogen’s longstanding collaboration with Ionis Pharmaceuticals, Inc. , We are encouraged by the available data and eager to move salanersen into the next stage of development as quickly as possible.” a leader in RNA-targeted therapeutics.

Therapies

Drug Target Review

JULY 21, 2025

Prior to WuXi AppTec, Dr Li held scientific leadership roles in CROs and pharmaceutical companies in Canada and Japan. Her expertise spans CRO oversight, regulatory strategy and CTD-compliant submissions for INDs and NDAs. She holds a PhD in pharmacology from Japan, and an MD and MSc from China.

Drug Development

Drug Patent Watch

JANUARY 14, 2025

In the fast-paced world of pharmaceuticals, negotiations play a pivotal role in shaping the industry’s landscape. Let’s dive into the intricacies of pharmaceutical negotiations, exploring valuable lessons, current trends, and strategies for success.

Pharmaceuticals

The Pharma Data

JUNE 9, 2025

According to Dr. Kelvin Tan , Chief Medical Affairs Officer at Jazz Pharmaceuticals, the data add to the growing body of evidence supporting sodium reduction as a modifiable risk factor. The new late-breaking data presented by Jazz Pharmaceuticals at SLEEP 2025 solidify Xywav’s position as a cornerstone treatment in narcolepsy management.

FDA Approval

Drug Target Review

DECEMBER 9, 2024

AI is influencing all industries, but its impact will be especially strong in pharmaceuticals where it is expected to accelerate drug discovery and, in clinical settings, generate patterns and insights from vast quantities of patient data to enable more personalised treatments.As

Engineering

The Pharma Data

JUNE 24, 2025

In this context, the USP’s mAb reference standards offer pharmaceutical manufacturers a critical benchmark. Through this collaboration, we’re reinforcing our commitment to advancing pharmaceutical quality by making science-based solutions more accessible and adaptable for developers of mAbs and gene therapies.”

Therapies

Drug Patent Watch

OCTOBER 28, 2024

The pharmaceutical industry relies heavily on Contract Development and Manufacturing Organizations (CDMOs) to streamline the drug development and manufacturing process. CDMOs provide a wide range of services that cater to the diverse needs of pharmaceutical companies, from early-stage development to commercial manufacturing.

Pharmaceutical Companies

Drug Target Review

FEBRUARY 10, 2025

Dr. Bock has previously held leadership roles at MD Anderson, Teva Pharmaceuticals, CoGenesys, and Human Genome Sciences. Based in Houston, TX, CTMC was established to accelerate patient access to impactful cell therapies by bridging cell therapy development and manufacturing with MD Andersons clinical trial capabilities.

Therapies